Evotec SE

EVT

Company Profile

  • Business description

    Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

  • Contact

    Essener Bogen 7
    22419 Hamburg
    Hamburg22419
    DEU

    T: +49 40560810

    E: [email protected]

    https://www.evotec.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    4,553

Stocks News & Analysis

stocks

The 5 best US dividend aristocrats to watch in 2026

How to avoid the dividend aristocrat trap.
stocks

Chart of the Week: Is CSL finally turning the ship around?

The beaten down healthcare giant remains cheap on turnaround potential.
stocks

ASX top pick remains cheap with narrowing brand focus

Shares remain cheap for ASX winemaker as the company narrows focus on high margin brands.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,836.7071.200.81%
CAC 408,202.7840.950.50%
DAX 4024,217.5922.280.09%
Dow JONES (US)49,918.78953.33-1.87%
FTSE 10010,315.0760.260.59%
HKSE24,249.29158.67-0.65%
NASDAQ25,169.50509.32-1.98%
Nikkei 22564,217.2738.000.06%
NZX 50 Index13,202.1651.49-0.39%
S&P 5007,266.99119.66-1.62%
S&P/ASX 2008,633.2069.700.81%
SSE Composite Index3,987.016.21-0.16%

Market Movers